To observe the therapeutic effect and safety of rituximab (anti-CD20 monoclonal antibody) in the treatment of refractory autoimmune hemolytic anemia (AIHA).

Anti-CD20 monoclonal antibody is well tolerated in 90% of the patients,though10% of them had hypersensitivity reactions and 4 patients had severe opportunistic infection.

Preparation and identification of monoclonal antibody against ginsenoside Rb1;

Development of monoclonal antibody against Fumonisin B_1 and ELISA-kit of quantitative analysis for Fumonisin B_1;

Determination of fipronil in water by ELISA based on monoclonal antibody;

Production and identification of monoclonal antibodies to chCD25;

Production and identification of monoclonal antibodies against proteinase activated receptor-1;

Expression and purification of recombinant nucleocapsid protein of SARS Coronavirus and preparation of its monoclonal antibodies;

Development and Characterization of MAb against Haemagglutinin of Highly Pathogenic H5 Avian Influenza Virus;

Preparation and characterization of non-agglutinating mAbs against membrane antigen on human erythrocytes;

Studies on the antithrombotic effects of anti-platelet mAb SZ-21 F(ab′)_2 fragment;

Observation to the stability of the McAb against the interior antigen of influenza A virus;

Preparation and Characterization of McAb against SARS-associated Coronavirus;

Establishment of Hybridoma Cell Secreting McAb Against DNA and Characterization of The Secreted McAb;